

## **AMENDMENTS TO THE SPECIFICATION**

Please insert the following new paragraph on page 1, before Field of the Invention:

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a national phase filing under 35 U.S.C. §371 of PCT/EP2005/002379, filed March 7, 2005, which in turn claims the benefit of Austrian Patent Application no. A 386/2004, filed March 5, 2004, from which applications priority is claimed pursuant to the provisions of 35 U.S.C. §119 and §120. This application is also a continuation-in-part of U.S. Patent Application Serial no. 11/356,405, filed February 16, 2006, which is a continuation of U.S. Patent Application Serial no. 10/932,043, filed September 2, 2004, now abandoned, from which applications priority is claimed pursuant to 35 U.S.C. §120. All of the foregoing applications are incorporated herein by reference in their entireties.

Please insert the following Abstract on new page 34:

### **ABSTRACT**

The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a tablet or granule, a specific release of active substance can be adjusted which is matched to the special genotype in the metabolism of tolperisone. At the same time, as a result of the very uniform and persistent release of tolperisone, the *in vivo* inversion of enantiomerically pure tolperisone that is known from the art can be adjusted in favour of the R(-) tolperisone which is prominent in muscle-relaxing therapy.

Attachment: Page 34 consisting of the Abstract